pericarditis(CORP-2)amulticentre,double-blind,placebo-：心包炎（corp-2）一项多中心，双盲，安慰剂—.pdfVIP

Articles Efficacy and safety of colchicine for treatment of multiple recurrences of pericarditis (CORP-2): a multicentre, double-blind, placebo-controlled, randomised trial Massimo Imazio, Riccardo Belli, Antonio Brucato, Roberto Cemin, Stefania Ferrua, Federico Beqaraj, Daniela Demarie, Silvia Ferr o, Davide Forno, Silvia Maestroni, Davide Cumetti, Ferdinando Varbella, Rita Trinchero, David H Spodick, Yehuda Adler Summary Background Colchicine is eff ective for the treatment of acute pericarditis and fi rst recurrences. However, conclusive Published Online data are lacking for the efficacy and safety of colchicine for treatment of multiple recurrences of pericarditis. March 30 2014 /10.1016/ S0140-6736(13)62709-9 Methods We did this multicentre, double-blind trial at four general hospitals in northern Italy. Adult patients with See Online/Comment multiple recurrences of pericarditis (≥two) were randomly assigned (1:1) to placebo or colchicine (0·5 mg twice daily /10.1016/ for 6 months for patients weighing more than 70 kg or 0·5 mg once daily for patients weighing 70 kg or less) in S0140-6736(14)60113-6 addition to conventional anti-inflammatory treatment